324 related articles for article (PubMed ID: 18954983)
21. 4-(Heteroarylaminomethyl)-N-(2-aminophenyl)-benzamides and their analogs as a novel class of histone deacetylase inhibitors.
Fréchette S; Leit S; Woo SH; Lapointe G; Jeannotte G; Moradei O; Paquin I; Bouchain G; Raeppel S; Gaudette F; Zhou N; Vaisburg A; Fournel M; Yan PT; Trachy-Bourget MC; Kalita A; Robert MF; Lu A; Rahil J; Robert Macleod A; Besterman JM; Li Z; Delorme D
Bioorg Med Chem Lett; 2008 Feb; 18(4):1502-6. PubMed ID: 18207391
[TBL] [Abstract][Full Text] [Related]
22. N-hydroxy-3-phenyl-2-propenamides as novel inhibitors of human histone deacetylase with in vivo antitumor activity: discovery of (2E)-N-hydroxy-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (NVP-LAQ824).
Remiszewski SW; Sambucetti LC; Bair KW; Bontempo J; Cesarz D; Chandramouli N; Chen R; Cheung M; Cornell-Kennon S; Dean K; Diamantidis G; France D; Green MA; Howell KL; Kashi R; Kwon P; Lassota P; Martin MS; Mou Y; Perez LB; Sharma S; Smith T; Sorensen E; Taplin F; Trogani N; Versace R; Walker H; Weltchek-Engler S; Wood A; Wu A; Atadja P
J Med Chem; 2003 Oct; 46(21):4609-24. PubMed ID: 14521422
[TBL] [Abstract][Full Text] [Related]
23. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
24. Structure-activity relationship studies of a series of novel delta-lactam-based histone deacetylase inhibitors.
Kim HM; Ryu DK; Choi Y; Park BW; Lee K; Han SB; Lee CW; Kang MR; Kang JS; Boovanahalli SK; Park SK; Han JW; Chun TG; Lee HY; Nam KY; Choi EH; Han G
J Med Chem; 2007 May; 50(11):2737-41. PubMed ID: 17477518
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents.
Guandalini L; Cellai C; Laurenzana A; Scapecchi S; Paoletti F; Romanelli MN
Bioorg Med Chem Lett; 2008 Sep; 18(18):5071-4. PubMed ID: 18723349
[TBL] [Abstract][Full Text] [Related]
26. HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells.
Wegener D; Deubzer HE; Oehme I; Milde T; Hildmann C; Schwienhorst A; Witt O
Anticancer Drugs; 2008 Oct; 19(9):849-57. PubMed ID: 18765999
[TBL] [Abstract][Full Text] [Related]
27. Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence.
Hanessian S; Auzzas L; Giannini G; Marzi M; Cabri W; Barbarino M; Vesci L; Pisano C
Bioorg Med Chem Lett; 2007 Nov; 17(22):6261-5. PubMed ID: 17892933
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives.
Suzuki T; Ando T; Tsuchiya K; Fukazawa N; Saito A; Mariko Y; Yamashita T; Nakanishi O
J Med Chem; 1999 Jul; 42(15):3001-3. PubMed ID: 10425110
[TBL] [Abstract][Full Text] [Related]
29. The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors.
Hamblett CL; Methot JL; Mampreian DM; Sloman DL; Stanton MG; Kral AM; Fleming JC; Cruz JC; Chenard M; Ozerova N; Hitz AM; Wang H; Deshmukh SV; Nazef N; Harsch A; Hughes B; Dahlberg WK; Szewczak AA; Middleton RE; Mosley RT; Secrist JP; Miller TA
Bioorg Med Chem Lett; 2007 Oct; 17(19):5300-9. PubMed ID: 17761416
[TBL] [Abstract][Full Text] [Related]
30. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
[TBL] [Abstract][Full Text] [Related]
31. Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
Kinzel O; Llauger-Bufi L; Pescatore G; Rowley M; Schultz-Fademrecht C; Monteagudo E; Fonsi M; Gonzalez Paz O; Fiore F; Steinkühler C; Jones P
J Med Chem; 2009 Jun; 52(11):3453-6. PubMed ID: 19441846
[TBL] [Abstract][Full Text] [Related]
32. Design and campaign synthesis of pyridine-based histone deacetylase inhibitors.
Andrews DM; Gibson KM; Graham MA; Matusiak ZS; Roberts CA; Stokes ES; Brady MC; Chresta CM
Bioorg Med Chem Lett; 2008 Apr; 18(8):2525-9. PubMed ID: 18378451
[TBL] [Abstract][Full Text] [Related]
33. Novel pyridinyl and pyrimidinylcarbazole sulfonamides as antiproliferative agents.
Hu L; Li ZR; Wang YM; Wu Y; Jiang JD; Boykin DW
Bioorg Med Chem Lett; 2007 Mar; 17(5):1193-6. PubMed ID: 17197178
[TBL] [Abstract][Full Text] [Related]
34. Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy.
Ontoria JM; Altamura S; Di Marco A; Ferrigno F; Laufer R; Muraglia E; Palumbi MC; Rowley M; Scarpelli R; Schultz-Fademrecht C; Serafini S; Steinkühler C; Jones P
J Med Chem; 2009 Nov; 52(21):6782-9. PubMed ID: 19888759
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.
Roberts WG; Ung E; Whalen P; Cooper B; Hulford C; Autry C; Richter D; Emerson E; Lin J; Kath J; Coleman K; Yao L; Martinez-Alsina L; Lorenzen M; Berliner M; Luzzio M; Patel N; Schmitt E; LaGreca S; Jani J; Wessel M; Marr E; Griffor M; Vajdos F
Cancer Res; 2008 Mar; 68(6):1935-44. PubMed ID: 18339875
[TBL] [Abstract][Full Text] [Related]
36. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.
Lee HY; Wang LT; Li YH; Pan SL; Chen YL; Teng CM; Liou JP
Org Biomol Chem; 2014 Nov; 12(44):8966-76. PubMed ID: 25277250
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.
Itoh Y; Suzuki T; Kouketsu A; Suzuki N; Maeda S; Yoshida M; Nakagawa H; Miyata N
J Med Chem; 2007 Nov; 50(22):5425-38. PubMed ID: 17929798
[TBL] [Abstract][Full Text] [Related]
38. Structure-activity relationship of alkyl 9-nitrocamptothecin esters.
Cao ZS; Pantazis P; Mendoza J; Early J; Kozielski A; Harris N; Giovanella B
Acta Pharmacol Sin; 2003 Feb; 24(2):109-19. PubMed ID: 12546717
[TBL] [Abstract][Full Text] [Related]
39. Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera.
Son IH; Chung IM; Lee SI; Yang HD; Moon HI
Bioorg Med Chem Lett; 2007 Sep; 17(17):4753-5. PubMed ID: 17662606
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group.
Chen PC; Patil V; Guerrant W; Green P; Oyelere AK
Bioorg Med Chem; 2008 May; 16(9):4839-53. PubMed ID: 18397827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
